Eisai Preps Eritoran For Phase III Sepsis Trial Based On Phase II Mortality Reduction
Closest competitor appears to be Takeda, which plans Phase III study this summer for its own TLR4 inhibitor for severe sepsis.
Closest competitor appears to be Takeda, which plans Phase III study this summer for its own TLR4 inhibitor for severe sepsis.